Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) fell 2.3% during mid-day trading on Monday . The stock traded as low as $4.16 and last traded at $4.21, with a volume of 68,026 shares trading hands. The stock had previously closed at $4.31.

Several brokerages have recently issued reports on ABEO. FBR & Co reissued a “buy” rating and set a $15.00 price objective on shares of Abeona Therapeutics in a research note on Sunday, May 22nd. Zacks Investment Research lowered shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, July 4th. Maxim Group restated a “buy” rating and set a $6.00 target price on shares of Abeona Therapeutics in a report on Tuesday, May 17th. Finally, Rodman & Renshaw restated a “buy” rating and set a $17.00 target price on shares of Abeona Therapeutics in a report on Wednesday, May 18th.

The stock’s market cap is $135.19 million. The company has a 50-day moving average price of $3.32 and a 200 day moving average price of $2.84.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings results on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by $0.06. Equities research analysts expect that Abeona Therapeutics Inc will post ($0.71) earnings per share for the current fiscal year.

Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.